Stem Sellouts
By Jesse Reynolds,
TomPaine.com
| 07. 19. 2005
Recent developments—both technical and political —have once again brought stem cell research to the front pages of newspapers across the country. Sens. Tom Harkin, D-Iowa, and Arlen Specter, R-Pa., are the sponsors of a bill in the Senate that would largely undo President Bush’s restrictive federal funding policies. It’s already passed the House, and is scheduled for a Senate vote this month. But now conservatives are working to dilute support for it by introducing several competing bills that would fund stem cell research that does not destroy human embryos.
Progressives are inclined to react to these reports by strengthening their support of stem cell research as an effective wedge issue to split Republicans. But before we move ahead with simplistic calls for more funding and fewer restrictions, we should pay heed to troubles with California’s new stem cell research agency— and to the larger implications of biotech boosterism.
California’s Calamity
Last fall, Californians approved Proposition 71, which established the Institute for Regenerative Medicine to distribute $3 billion in stem cell research grants. Voters were swayed, with the help of a...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...